Accuray Incorporated's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Accuray Incorporated's ROA in the fourth quarter of 2026?
Accuray Incorporated recorded a cumulative net loss of $-49 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -9.7%.

However, within the Healthcare sector 298 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3189, from total ROA ranking in the third quarter of 2026 at 3626.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	27.85 %	-4.48 %	7.45 %	8.13 %	9.26 %
Y / Y Net Income Change	-	-	-	-	-66.84 %
Net Income (TTM) in million	-49	-46	-36	-19	-2
Return On Assets (TTM)	-9.7 %	-9.75 %	-7.44 %	-4.11 %	-0.34 %
ARAY's Total Ranking	# 3189	# 3626	# 2975	# 2621	# 2545
Total Assets (TTM) in million	619	462	470	477	485
Seq. Total Assets Change	34.18 %	-1.71 %	-1.58 %	-1.51 %	0.25 %
Seq. Net Income Change	-	-	-	-	-

ARAY's 5 Years Annual ROA >> Back to ARAY Management Effectiveness >> Compare ARAY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 95
Sector	# 299
Overall	# 3195

Return On Assets Statistics
High	Average	Low
2.88 %	-6.13 %	-24.6 %
(Sep 30 2020)		(Mar 31 2013)

Financial Statements
Accuray Incorporated's Assets	$ 619 million	ARAY's Balance sheet
Accuray Incorporated's Income	$ -2 million	Quarterly ARAY's Income Statement
ARAY's Income by Division		See ARAY's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	41.11 %	0.43 %	-4.03 %	-0.85 %	-0.33 %
Total Assets in million	619	439	437	455	459
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-49	-2	-16	-9	-5
Annual Return On Assets	-7.94 %	-0.36 %	-3.56 %	-2.04 %	-1.16 %

ARAY's 5 Years Annual ROA >> Back to ARAY Management Effectiveness >> Compare ARAY ROA to its Competitors

More Return On Assets Ratios
ARAY's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARAY's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARAY's Competitors
Subscribers only: Roa for Accuray Incorporated's Suppliers
Subscribers only: Return On Assets for ARAY's Customers

You may also want to know
ARAY's Roi	ARAY's Inventory Turnover Ratio	ARAY's Growth Rates	ARAY's Dividend Comparisons
	ARAY's Profitability Ratios	ARAY's Asset Turnover Ratio	ARAY's Dividend Growth
ARAY's Roe	ARAY's Valuation Ratios	ARAY's Financial Strength Ratios	ARAY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-29T04:46:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.